GLP-1 receptor agonists × glycemic control

SynthesisPLoS medicine2026

Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies.

Jędrzej Chrzanowski et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 2026

Randomised comparison

Probably raised glycemic control

2.2×1.7× to 2.7×

Bigger than 5 in 10 for glycemic control

As reported

HR 2.17, 95% CI 1.73–2.74

Randomised comparison

Probably raised glycemic control

2.1×1.6× to 2.8×

Bigger than 5 in 10 for glycemic control

As reported

HR 2.13, 95% CI 1.60–2.83

Randomised comparison

Probably raised glycemic control

1.3× to 3×

Bigger than 4 in 10 for glycemic control

As reported

HR 1.96, 95% CI 1.28–2.99

Three numbers in the abstract

the abstract, start to end

glucose-lowering regimens (HR 2.17, 95% CI [1.73, 2.74]; p < 0.001), regimens excluding other GLP-1 receptor agonists (HR 2.13, 95% CI [1.60, 2.83]; p < 0.001), and sodium-glucose co-transporter 2 inhibitor (SGLT2i) users (HR 1.96, 95% CI [1.28, 2.99];

← favours treatmentfavours comparator →
could be chance
Glycemic control
HR 2.171.73–2.74
Glycemic control
HR 2.131.60–2.83
Glycemic control
HR 1.961.28–2.99
GLP-1 receptor agonistsOther glucose-loweringGlycemic control
1 / 3

Not cited yet

Full record →Abstract, authors, funding and every citing paper · PMID 42166479